Original document(63 pages) Authorized document(59 pages) 中文版
    Compounds of the formula I wherein R is lower-alkyl, R1 is halogen, R2 is C1-C12-alkyl, R3 is hydroxy, lower-alkoxy, lower-alkyl-carbonyloxy, lower-alkoxy-lower-alkylcarbonoyloxy, lower-alkylaminocarbonyloxy, arylaminocarbonyloxy or aryl-lower alkylaminocarbonyloxy, X is C1-C18-alkylene which optionally can be interrupted by 1,4-phenylene or interrupted or lengthened by 1,4-cyclohexylene, A is di- or tri-substituted 2-imidazolyl attached via an ethylene group or a substituted or unsubstituted heterocycle selected from the group consisting of benzimidazolyl, benzimidazolonyl, imidazo[4,5-c]pyridinyl, imidazo[4,5-c]pyridinonyl, benzthiazolyl, benzodiazepine-2,5-dion-1-yl and pyrrolo[2,1-c]-[1,4]benzodiazepine-5,11-dion-10-yl and n is the number 0 or 1, in the form of racemates and optical antipodes, as well as N-oxides and pharmaceutically usable acid addition salts thereof. The compounds of formual I have a pronounced calcium-antagonistic and anti-arrhythmic activity and can accordingly be used as medicaments, especially for the control or prevention of angina pectoris, ischaemia, arrhythmias, high blood pressure and cardiac insufficiency.
Application Number
申请号
87107875 Application Date
申请日
1987.11.13
Title 名称 Tetrahydronaphthalene derivatives
Publication Number
公开号
1018531 Publication Date
公开日
1988.05.25
Approval Pub. Date 1995.06.21 Granted Pub. Date 1995.06.21
International Classification 分类号 C07D233/64;C07D235/14;C07D277/62;C07D471/04
Applicant(s) Name
申请人
F.Hoffman-La Roche & Co.
Address 地址
Inventor(s) Name 发明人 Quirico Branca;Roland Jaunin
Attorney & Agent 代理人 YANG JIUCHANG
More information 更  多  信  息


 Related patents information
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.